Charles Schwab’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-284,649
| Closed | -$453K | – | 3729 |
|
|
2024
Q1 | $453K | Buy |
284,649
+5,945
| +2% | +$8.82K | ﹤0.01% | 3064 |
|
|
2023
Q4 | $239K | Buy |
278,704
+3,640
| +1% | +$3.2K | ﹤0.01% | 3255 |
|
|
2023
Q3 | $294K | Buy |
275,064
+3,376
| +1% | +$6.99K | ﹤0.01% | 3218 |
|
|
2023
Q2 | $704K | Sell |
271,688
-53,436
| -16% | -$191K | ﹤0.01% | 2897 |
|
|
2023
Q1 | $1.33M | Sell |
325,124
-2,850
| -0.9% | -$13.2K | ﹤0.01% | 2638 |
|
|
2022
Q4 | $1.65M | Buy |
327,974
+13,415
| +4% | +$84.1K | ﹤0.01% | 2624 |
|
|
2022
Q3 | $4.12M | Buy |
314,559
+2,884
| +0.9% | +$43.7K | ﹤0.01% | 2312 |
|
|
2022
Q2 | $4M | Buy |
311,675
+12,128
| +4% | +$168K | ﹤0.01% | 2291 |
|
|
2022
Q1 | $4.57M | Buy |
299,547
+19,079
| +7% | +$298K | ﹤0.01% | 2320 |
|
|
2021
Q4 | $4.97M | Buy |
280,468
+5,222
| +2% | +$100K | ﹤0.01% | 2359 |
|
|
2021
Q3 | $5.79M | Buy |
275,246
+93,136
| +51% | +$2.05M | ﹤0.01% | 2302 |
|
|
2021
Q2 | $3.59M | Buy |
182,110
+18,137
| +11% | +$425K | ﹤0.01% | 2510 |
|
|
2021
Q1 | $4.77M | Buy |
163,973
+32,474
| +25% | +$909K | ﹤0.01% | 2323 |
|
|
2020
Q4 | $3.98M | Buy |
131,499
+1,839
| +1% | +$40.2K | ﹤0.01% | 2332 |
|
|
2020
Q3 | $2.06M | Buy |
129,660
+47,599
| +58% | +$868K | ﹤0.01% | 2483 |
|
|
2020
Q2 | $1.62M | Buy |
82,061
+1,354
| +2% | +$25.9K | ﹤0.01% | 2487 |
|
|
2020
Q1 | $996K | Buy |
80,707
+1,655
| +2% | +$27K | ﹤0.01% | 2492 |
|
|
2019
Q4 | $1.46M | Buy |
79,052
+38,591
| +95% | +$564K | ﹤0.01% | 2494 |
|
|
2019
Q3 | $561K | Buy |
40,461
+1,974
| +5% | +$29.6K | ﹤0.01% | 2757 |
|
|
2019
Q2 | $564K | Buy |
+38,487
| New | +$563K | ﹤0.01% | 2756 |
|
Charles Schwab's NGM Position: Q2 2024 in Review
Charles Schwab sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 284,649 shares — an estimated $453K sold.
Charles Schwab first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $5.79M in Q3 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Charles Schwab reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Charles Schwab sold 284,649 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $453K.
- Charles Schwab first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
- Charles Schwab's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $5.79M in Q3 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Charles Schwab's 13F filing for Q2 2024, filed 12 Aug 2024.